All stock lists
Monopar Therapeutics (NASDAQ:MNPR)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
70.53-0.13 (-0.18%)
Insider Score
––Not scored
MNPR Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
MNPR Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Growth (YoY) | — | — | — | — | — | — |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A Expense | 1.88 M | 1.74 B | 2.21 M | 1.50 M | 1.50 M | 1.58 M |
| R&D Expense | 4.77 M | 3.49 M | 3.94 M | 2.59 M | 1.73 M | 1.64 M |
| Operating Expenses | 6.64 M | 5.23 M | 6.16 M | 4.09 M | 3.23 M | 3.22 M |
| Operating Income | -6.64 M | -5.23 M | -6.16 M | -4.09 M | -3.23 M | -3.22 M |
| Pretax Income | -5.31 M | -3.89 M | -5.20 M | -3.44 M | -2.45 M | -2.62 M |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -5.31 M | -3.89 M | -5.20 M | -3.44 M | -2.45 M | -2.62 M |
| EPS (Basic) | -0.62 | -0.46 | -0.78 | -0.48 | -0.35 | -0.38 |
| EPS (Diluted) | -0.62 | -0.46 | -0.78 | -0.48 | -0.35 | -0.38 |
| Shares Outstanding | 8.54 M | 8.54 M | 6.69 M | 7.12 M | 7.00 M | 6.91 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.